



ROS Therapeutics receives 10M DKK in Equity and Loan Financing.

October 05, 2020

ROS Therapeutics today disclosed that it received 10M DKK in a combination of equity financing through private investors as well as a loan from the Danish Growth Fund facilitated through a COVID-19 business angel matching loan. At the same time, business angel Morten Sandlykke joined the Company's board.

"I am very happy that we succeeded in this financing round during uncertain times and thrilled that we have now raised adequate capital to bring Trexior™ to clinical proof of concept. This will be a major step forward in our ambition towards helping children with juvenile idiopathic arthritis (JIA) and their parents", says Hanne Damgaard Jensen, CEO.

About Trexior™: Trexior is an innovative proprietary and potentially best-in-class orally delivered methotrexate therapy. Several of the shortcomings of existing methotrexate therapies, whether oral or injections, are sought overcome with Trexior.

About methotrexate: Methotrexate is a cornerstone treatment for JIA, one of the most common childhood diseases as well as for rheumatoid arthritis (RA), a common autoimmune inflammatory disease of adults. Since the early 90'ies, MTX has had a secure place in the treatment of these diseases and has been shown to have a synergistic relationship with biological therapies.

About ROS Therapeutics: ROS Therapeutics ApS is a development stage pharmaceutical company, committed to optimize the treatment experience with methotrexate and address unmet needs of children with JIA and other autoimmune and chronic inflammatory conditions.

For further information please contact:

Hanne Damgaard Jensen, CEO ROS Therapeutics; hdj@rosterapeutics.com;
Tel: +45 4078 6888